NCT05102370View on ClinicalTrials.gov

A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 6, 2021

Primary Completion Date

October 6, 2025

Study Completion Date

October 6, 2025

Conditions
Clonal Cytopenia of Undetermined SignificanceCCUS Clonal Cytopenia of Undetermined Significance
Interventions
DRUG

Enasidenib

Study participants will receive enasidenib 100 mg daily for 18 months. Participants will continue treatment with enasidenib until confirmed progression to AML or MDS, development of unacceptable toxicity, or suspicion of disease progression, provided the patient is deriving clinical benefit, which will be determined at the discretion of the principal investigator.

Trial Locations (12)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre

11725

Memorial Sloan Kettering Suffolk-Commack (Limited protocol activities), Commack

43210

Ohio State University (Data Collection Only), Columbus

44195

Cleveland Clinic (Data Collection Only), Cleveland

55905

Mayo Clinic (Data Collection Only), Rochester

63110

Washington University (Data Collection and Specimen Analysis), St Louis

97239

Oregon Health & Science University (Data Collection Only), Portland

07920

Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (All protocol activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER